IMPORTANT INFORMATION

  • CFTR.info is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.

ABBREVIATED TERMS & CONDITIONS

  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.

 

I have read and understood the above

Drug & research development » Clinical trials » NCT00004779

Phase I Pilot Study of Ad5-CB-CFTR, an Adenovirus Vector Containing the Cystic Fibrosis Transmembrane Conductance Regulator Gene, in Patients With Cystic Fibrosis

Official title: Not provided

Clinical Trials gov number: NCT00004779

Click on the tabs to move through the sequence.

Purpose: To assess the safety and efficacy of gene transfer into the nasal epithelium using Ad5-CB-CFTR, an E1-deleted adenovirus vector containing the CF transmembrane conductance regulator gene, in CF patients.

To determine whether ion transport abnormalities in CF airway cells can be corrected.

Phase: 1

Type: Interventional

Study sponsor: National Center for Research Resources (NCRR); University of North Carolina

Disease characteristics

    -No mild genetic mutations, i.e., normal nasal chloride ion permeability

    -≥2 weeks since decrease in pulmonary function

Prior/concurrent therapy

    -≥3 months since systemic cortisone

    -≥1 month since other therapeutic research study, e.g., DNAse

Patient characteristics

    -Adequate endocrine, liver, kidney, and cardiac function

    -Adenovirus antibody seropositive

    -No pregnant or nursing women

    -Negative pregnancy test required of fertile women

    -Adequate contraception required of fertile patients

Intervention
Ad5-CB-CFTR, Genetic

Geographical Location
No contacts or locations provided

Number of Participants
≤50 (Not Available)

Primary Endpoint

Not provided

Secondary Endpoint

Not provided

Click on the tabs to move through the sequence.

Groups of 3 patients receive 1 of 4 doses of Ad5-CB-CFTR, a recombinant E1-deleted adenovirus serotype 5 vector containing the cystic fibrosis transmembrane conductance regulator gene. Ad5-CB-CFTR is administered to 1 nasal cavity and the vehicle alone is administered to the opposite nasal cavity as the control.

View Trial Results